While training in otolaryngology–head and neck surgery in Australia, Somnair Sleep co-founder and CEO Anders Sideris, Engr ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C.

Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. The stock jumped 42%, to ...

Positive opinion for TEVIMBRA in combination with chemotherapy as a first-line treatment of nasopharyngeal cancer (NPC) based on results of RATIONALE-309 study demonstrating statistically ...

BioCryst Pharmaceuticals, Inc. announced promising new data regarding their oral prophylactic treatment, ORLADEYO (berotralstat), for hereditary angioedema (HAE) during the 14th C1-Inhibitor ...

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data Jun. 02, 2025 2:55 PM ET Kymera Therapeutics, Inc. (KYMR) Stock SNY , REGN , SNYNF , KYMR 1 Comment Terry Chrisomalis ...

Real-world treatment patterns and outcomes in HER2-positive metastatic breast cancer patients with brain metastases.. JCO 43 , e13022-e13022 (2025). DOI: 10.1200/JCO.2025.43.16_suppl.e13022 ...

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to ...

The discovery of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) represented a groundbreaking advancement, shifting the treatment paradigm of these diseases ...